Serina Therapeutics reported financial results for the quarter ended June 30, 2026, reporting a net loss of $8.9 million, or $(0.55) per share, compared to a $6.6 million loss in the prior year period. Operating expenses increased to $6.8 million from $5.7 million, driven by higher R&D and G&A costs. The company completed enrollment and dosing of all eight patients in Cohort 1 of its Phase 1b registrational study for SER-252 ahead of schedule, with top-line data targeted for the first half of 2027. Cash and cash equivalents rose to $23.0 million as of June 30, 2026. The company also appointed Farrell Simon to its Board of Directors. Serina Therapeutics is a clinical-stage biotechnology company developing drug candidates using its proprietary POZ Platform technology for neurological diseases.
